| CAS NO: | 269730-03-2 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| Cas No. | 269730-03-2 |
| 化学名 | 1,3-dihydro-3-[(4-hydroxyphenyl)methylene]-5,6-dimethoxy-2H-indol-2-one |
| Canonical SMILES | COC1=C(OC)C=C(/C(C(N2)=O)=C/C3=CC=C(O)C=C3)C2=C1 |
| 分子式 | C17H15NO4 |
| 分子量 | 279.3 |
| 溶解度 | ≤1mg/ml in ethanol;10mg/ml in DMSO;15mg/ml in dimethyl formamide |
| 储存条件 | Store at -20℃ |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | RPI-1 is an ATP-dependent Ret tyrosine kinase and inhibitor [1]. RPI-1 also inhibits c-Met activation and expression [2]. The ret proto-oncogene encodes a receptor protein tyrosine kinase involved in the etiology of human tumors. RET loss of function mutations are associated with the development of Hirschsprung's disease, and gain of function mutations are associated with the development of various types of human cancer, including medullary thyroid carcinoma, multiple endocrine neoplasias, pheochromocytoma and parathyroid hyperplasia. In NIH3T3 fibroblasts expressing the Ret/ptc1 target tyrosine kinase (NIH3T3ptc1), RPI-1 preferentially inhibited the anchorage-independent growth with IC50 value of 0.97 μM [1]. In the N592 SCLC and H460 NSCLC cell lines, RPI-1 dose-dependently inhibited Met phosphorylation. In H460 cells, RPI-1 also inhibited HGF-induced Met tyrosine phosphorylation in a dose-dependent way [2]. In mice implanted s.c. with H460 cells, RPI-1 with 100 and 150 mg/kg significantly reduced the mean number of macroscopic lung metastases by 57% and 75%, respectively. In primary s.c. growing H460 tumors, RPI-1 exhibited significant antiangiogenic effect [2]. References: |
m.cnreagent.com